Results 31 to 40 of about 252,991 (337)

Neuroinflammation in Alzheimer's disease [PDF]

open access: yesThe Lancet Neurology, 2015
Increasing evidence suggests that Alzheimer's disease pathogenesis is not restricted to the neuronal compartment, but includes strong interactions with immunological mechanisms in the brain. Misfolded and aggregated proteins bind to pattern recognition receptors on microglia and astroglia, and trigger an innate immune response characterised by release ...
Olga Garaschuk   +41 more
openaire   +11 more sources

APOE in the bullseye of neurodegenerative diseases: impact of the APOE genotype in Alzheimer’s disease pathology and brain diseases

open access: yesMolecular Neurodegeneration, 2022
ApoE is the major lipid and cholesterol carrier in the CNS. There are three major human polymorphisms, apoE2, apoE3, and apoE4, and the genetic expression of APOE4 is one of the most influential risk factors for the development of late-onset Alzheimer's ...
Rosalía Fernández-Calle   +11 more
doaj   +1 more source

Neuroinflammation in Synucleinopathies

open access: yesBrain Pathology, 2016
AbstractThe causes of most neurodegenerative diseases are attributed to multiple genetic and environmental factors interacting with one another. Above all, inflammation in the nervous system has been implicated in many neurodegenerative diseases. Still, the roles of neuroinflammation in disease mechanisms and the triggers of inflammatory responses in ...
Somin Lim   +3 more
openaire   +4 more sources

Imidazopyridazine Acetylcholinesterase Inhibitors Display Potent Anti-Proliferative Effects in the Human Neuroblastoma Cell-Line, IMR-32

open access: yesMolecules, 2021
Imidazo[1,2-b]pyridazine compounds are a new class of promising lead molecules to which we have incorporated polar nitro and amino moieties to increase the scope of their biological activity.
Rakesh Kumar Sharma   +7 more
doaj   +1 more source

Neuroinflammation in Alzheimer’s Disease [PDF]

open access: yesBiomedicines, 2021
Alzheimer’s disease (AD) is a neurodegenerative disease associated with human aging. Ten percent of individuals over 65 years have AD and its prevalence continues to rise with increasing age. There are currently no effective disease modifying treatments for AD, resulting in increasingly large socioeconomic and personal costs.
Isaac G. Onyango   +4 more
openaire   +4 more sources

Targeting neuroinflammation in Alzheimer’s disease [PDF]

open access: yes, 2016
Almost 47 million people suffer from dementia worldwide, with an estimated new case diagnosed every 3.2 seconds. Alzheimer’s disease (AD) accounts for approximately 60%–80% of all dementia cases. Given this evidence, it is clear dementia represents one
Bronzuoli, MARIA ROSANNA   +3 more
core   +1 more source

Early-life stress elicits peripheral and brain immune activation differently in wild type and 5xFAD mice in a sex-specific manner

open access: yesJournal of Neuroinflammation, 2022
Background The risk of developing Alzheimer’s disease (AD) is modulated by genetic and environmental factors. Early-life stress (ELS) exposure during critical periods of brain development can impact later brain function and health, including increasing ...
S. Bachiller   +12 more
doaj   +1 more source

Neuroinflammation, Mast Cells, and Glia: Dangerous Liaisons [PDF]

open access: yes, 2017
The perspective of neuroinflammation as an epiphenomenon following neuron damage is being replaced by the awareness of glia and their importance in neural functions and disorders.
Alhouayek M   +183 more
core   +1 more source

Neuroinflammation and structural injury of the fetal ovine brain following intra-amniotic Candida albicans exposure. [PDF]

open access: yes, 2016
BackgroundIntra-amniotic Candida albicans (C. Albicans) infection is associated with preterm birth and high morbidity and mortality rates. Survivors are prone to adverse neurodevelopmental outcomes.
AJ Wolfberg   +63 more
core   +10 more sources

FTY720 (fingolimod) modulates the severity of viral-induced encephalomyelitis and demyelination. [PDF]

open access: yes, 2014
BackgroundFTY720 (fingolimod) is the first oral drug approved by the Food and Drug Administration for treatment of patients with the relapsing-remitting form of the human demyelinating disease multiple sclerosis.
Blanc, Caroline A   +2 more
core   +1 more source

Home - About - Disclaimer - Privacy